



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Risk factors and drug resistance of adult community-acquired urinary tract infections caused by *Escherichia coli*-producing extended spectrum $\beta$ -lactamase in the Chongqing region, China: A 5-year retrospective analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2024-090665
Article Type:	Original research
Date Submitted by the Author:	01-Jul-2024
Complete List of Authors:	Zhou, Yan-ling; The Affiliated Dazhu Hospital of Chongqing Medical University, Department of Infectious Disease Long, Biao-li; The Affiliated Dazhu Hospital of Chongqing Medical University, Department of Infectious Disease Liu, He-lei; The Affiliated Dazhu Hospital of Chongqing Medical University, Department of Infectious Disease Wu, Jing; The Affiliated Dazhu Hospital of Chongqing Medical University, Department of Infectious Disease Xia, Hong; The Affiliated Dazhu Hospital of Chongqing Medical University, Department of Infectious Disease
Keywords:	Urinary tract infections < UROLOGY, PUBLIC HEALTH, Adult urology < UROLOGY

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

# Risk factors and drug resistance of adult community-acquired urinary tract infections caused by *Escherichia coli*-producing extended spectrum $\beta$ -lactamase in the Chongqing region, China: A 5-year retrospective analysis

Yan-ling Zhou<sup>1\*</sup>, Biao-li Long<sup>1\*</sup>, He-lei Liu<sup>1</sup>, Jing Wu<sup>1#</sup>, Hong Xia<sup>1#</sup>

<sup>1</sup>Department of Infectious Disease, The Affiliated Dazu Hospital of Chongqing Medical University, Chongqing 402360, China

\*Authors contributed equally

#Correspondence: Jing Wu 2861914532@qq.com ; Hong Xia 2544775799@qq.com

## ABSTRACT:

**Objective:** To evaluate the prevalence, resistance, and risk factors of community-acquired urinary tract infections (CAUTIs) caused by extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli* (ESBL-EC) for providing a basis for the selection of clinical therapeutic agents

**Methods:** We retrospectively analyzed the clinical data of patients diagnosed with CAUTIs caused by *E. coli* from May 2017 to December 2022 at a tertiary hospital in the Chongqing region, China, and evaluated the detection rate of ESBL-EC. To assess the risk factors for CAUTIs caused by ESBL-EC, a case-control design was used, focusing on the resistance of ESBL-EC.

**Results:** In total, 394 cases of CAUTIs caused by *E. coli* were included; 192 cases were ESBL-positive, with a detection rate of 48.7% (192/394). Parenchymal tumor, history of urolithiasis stone fragmentation, history of urological surgery, hospitalization within 6 months, indwelling urinary catheter insertion within 6 months, and antibiotic use (mainly third-generation cephalosporins) were the factors significantly associated with CAUTIs caused by ESBL-EC ( $P < 0.05$ ) through logistic regression for univariate analysis. Multivariate analysis revealed that a history of urolithiasis stone fragmentation, urological surgery, indwelling urinary catheter insertion within 6 months, hospitalization within 6 months, and use of third-generation cephalosporins were the independent risk factors for CAUTIs caused by ESBL-EC. Analysis of resistance in ESBL-EC revealed that the sensitivity of carbapenems, including imipenem, meropenem, and ertapenem; amikacin; cefotetan; piperacillin/tazobactam; nitrofurantoin; and cefoperazone/sulbactam was 100%, 100%, 96.6%, 95.3%, 87.9%, and 76.5%, respectively. Penicillins, cephalosporins, and quinolones were associated with higher antibiotic resistance rates.

**Conclusions:** Our results revealed high ESBL-EC detection rates. CAUTIs caused by ESBL-EC are more likely to occur in patients with parenchymal tumor, a history of urolithiasis stone fragmentation, a history of urological surgery, hospitalization within 6 months, indwelling urinary catheter insertion within 6 months, and use of third-generation cephalosporins. These patients were

highly resistant to penicillins, cephalosporins, and quinolones.

**Key Words:** Drug Resistance; Community-acquired Urinary Tract Infections; *Escherichia Coli*-producing Extended Spectrum  $\beta$ -Lactamase; Adult

**Strengths and limitations of this study**

This study incorporated nearly 200 cases of community-acquired urinary tract infections (CAUTIs) caused by extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli* (ESBL-EC) .

The study employed a case-control design to analyze the risk factors o urinary tract infections caused by ESBL-EC.

This study analyzed the drug resistance of ESBL-EC.

The study utilized the disk diffusion method for confirmation of bacterial phenotypes, without conducting genetic sequencing at the molecular level.

1 Introduction

Urinary tract infection (UTI), characterized by bacterial resistance and recurrence, is one of the most common infections in the community, with urinary-derived *Escherichia coli* being the most predominant pathogenic bacteria. *E. coli* has shown more complex changes in drug resistance, more rapid geographic variation, and a faster transmission rate with the widespread use of antimicrobials. The establishment of long-term surveillance and analysis of drug resistance in *E. coli* are being focused on globally to find a faster treatment method for *E. coli* infections and control the epidemic of novel drug-resistant strains [1, 2].

The current worldwide prevalence of extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli* (ESBL-EC) in the community is increasing, causing a significant issue in clinical diagnosis and treatment [1, 2]. Laboratory studies have reported that ESBL-producing *Enterobacteriaceae* can produce several  $\beta$ -lactamases to hydrolyze broad-spectrum  $\beta$ -lactamase antibiotics, thus leading to resistance to penicillins and cephalosporins [3]. Moreover, genes encoding ESBL can be transferred in different species of plasmid-mediated *Enterobacteriaceae* [4]; therefore, bacteria carrying ESBL genes usually comprise additional genes or gene mutations that mediate resistance to multiple antibiotics [5].

Reviewing the literature over the past 20 years approximately, we found reports about the genetic and epidemic characteristics, drug resistance patterns, and susceptibility factors of *E. coli* from China, the United States, the United Kingdom, Australia, Spain, Turkey, Jordan, and other countries [7-15]; the results from these studies have been used in the empirical treatment and development of related drugs in the clinic. In China, a well-established surveillance system for drug-resistant bacteria was formed quite late; therefore, relatively few reports about the bacteria are available, and more surveillance data and laboratory studies are still required to help doctors choose the appropriate

treatment. Thus, we herein retrospectively analyzed cases of community-acquired urinary tract infections (CAUTIs) caused by *E. coli* within the past 5 years in the Chongqing region, China, evaluated the drug resistance and clinical characteristics of ESBL-EC and analyzed the risk factors for CAUTIs caused by ESBL-EC by performing a case-control study in ESBL-positive and -negative patients.

## 2 Method

### 2.1 Environment and Population

The Dazu Affiliated Hospital of Chongqing Medical University, Dazu District, Chongqing, China, is a national tertiary general hospital integrating medical, teaching, scientific research, preventive health care, first aid, and rehabilitation, with a bed capacity of 1000 and receives more than 8000 patients per year. The Dazu district, located in the western part of Chongqing, has a resident population of 8,56,000, and the region has a high degree of population aging, with a large population suffering from common diseases such as diabetes, cardiovascular disease, respiratory disease, and cancer.

### 2.2 Study Design and Materials

We herein retrospectively reviewed patients diagnosed with CAUTIs caused by *E. coli* diagnosed from May 2017 to December 2022. We collected data including sex, age, admission time, sample collection time, clinical manifestations, and risk factors (including underlying disease, history of urologic surgery, hospitalization within 6 months, antibiotic use within 6 months, and indwelling urinary catheter insertion within 6 months) through electronic medical records, examination reports, and telephone call back visits.

The risk factors for CAUTIs caused by ESBL-EC were evaluated using a case-control design, defining patients who were diagnosed with UTIs and had an ESBL-positive urine culture as the case group and patients who were diagnosed with UTIs and had an ESBL-negative urine culture as the control group, using logistic regression for univariate analysis. Multivariate analysis was performed for variables with significant differences ( $P < 0.05$ ).

### 2.3 Inclusion and Exclusion Criteria

The inclusion criteria were as follows: (1) patients older than 18 years; (2) those with urine collection done before admission or within 48 h of admission; (3) those with a positive urine culture with a growth of  $10^5$  CFU/mL; (5) those with a clinical diagnosis of UTI.

The exclusion criteria were as follows: (1) Patients with incomplete clinical data; (2) those who did not agree to provide case information for participation in the study; (3) those who were hospitalized for more than 48 h before diagnosis.

### 2.4 Microbiological Methods

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

The isolated *E. coli* were initially screened using the conventional paper chip diffusion method to detect the susceptibility to broad-spectrum  $\beta$ -lactamase antibiotics. The phenotypic confirmation of ESBL-EC was performed using the two-paper diffusion method according to the Clinical and Laboratory Standards Institute performance standards.

**2.5 Antimicrobial Susceptibility Testing**

The minimum inhibitory concentration was determined according to the Clinical and Laboratory Standards Institute guidelines [6], and the standard strain *E. coli* ATCC25922 was used as the control strain. Drugs including, ampicillin, ampicillin/sulbactam, piperacillin/tazobactam, meloxicillin, cefuroxime, cefoperazone/sulbactam, cefotetan, ceftazidime, ceftriaxone, cefixime, cefepime, cefotaxime, aztreonam, imipenem, meropenem, ertapenem, gentamicin, tobramycin, amikacin, levofloxacin, ciprofloxacin, nitrofurantoin, and cotrimoxazole, were tested.

**2.6 Statistical Analysis**

Analyses were performed using SPSS 26.0 (IBM Corp., Armonk, NY, USA). Count data were expressed as numbers and percentages, and chi-square tests were performed. Measurements that met normal distribution were presented as mean  $\pm$  standard deviation and were subjected to a t-test. Binary logistic regression was used to analyze the risk factors for CAUTIs caused by ESBL-EC, and  $P < 0.05$  was considered statistically significant.

**2.7 Patient and public involvement**

Patients and their guardians were not involved in the design and implementation of our study. Patients were not invited to contribute to the writing or editing of this manuscript. The main results of this study will be disseminated to patients and the public in an appropriate manner and seek their participation in the future.

**3 Results**

**3.1 Detection Rate**

A total of 394 cases diagnosed with CAUTIs caused by *E. coli* were included. Among them, 192 cases were ESBL-positive, with a detection rate of 48.7% (192/394).

**3.2 Clinical Characteristics of ESBL-Positive Patients**

Of the 192 ESBL-positive patients, 50 were male, accounting for 26.0% (50/192). The mean patient age was  $64 \pm 13$  years, and 62.0% (119/192) of the patients were aged 60 years and older. The vast majority of patients had underlying comorbidities, including diabetes, hypertension, parenchymal tumors, prostatic hyperplasia, and others.



The main clinical symptoms included urinary tract irritation signs (urinary frequency: 65, urinary urgencies: 56, and odynuria: 49), dysuria (11), hematuria (19), lumbago (28), pain with percussion in the renal area (21), and fever (35); the detailed results are shown in Table 1.

**Table 1: Clinical presentation and proportion of ESBL-positive patients**

Symptoms	Number	Percent(%)
Urinary irritation		
urinary frequency	65	33.9
urinary urgency	56	29.2
Odynuria	49	25.5
Dysuria	11	5.7
Hematuria	19	9.9
Lumbago	28	14.6
Renal buckle pain	21	10.9
Fever	35	18.2
Chilly	16	8.3
Shiver	6	3.1
Dizzy	12	6.3
Headache	18	9.4
Nausea	11	5.7
Vomit	17	8.9
Belly distention	14	7.3
Diarrhea	2	1.0

### 3.3 Risk Factors

Univariate analysis showed that parenchymal tumor, history of urolithiasis stone fragmentation, history of urological surgery, hospitalization within 6 months, indwelling urinary catheter insertion within 6 months, and antibiotic use (mainly third-generation cephalosporins) within 6 months were factors significantly associated with CAUTIs caused by ESBL-EC ( $P < 0.05$ , see Table 2).

Multivariate analysis of these factors revealed that a history of urolithiasis stone fragmentation, urological surgery, indwelling urinary catheter insertion within 6 months, hospitalization within 6 months, and use of third-generation cephalosporins were independent risk factors for CAUTIs caused by ESBL-EC (see Table 3).

**Table 2: Univariate analysis of the risk factors in ESBL-positive patients**

Risk factors	All patients (%)	ESBL-negative (%)	ESBL-positive (%)	<i>P</i> value
Total	394	202(51.3)	192 (48.7)	
Gender (male)	109(27.9)	59(29.2)	50(26.0)	0.483
Advanced age ( $\geq 60$ years)	227(57.6)	108(53.5)	119(62.0)	0.088
Underlying diseases and comorbidity				
Diabetes	161(40.9)	86(42.6)	75(39.1)	0.479



Hypertension	142(36.0)	68(33.7)	74(38.5)	0.314
Parenchymal tumor	43(10.9)	17(8.4)	26(13.5)	<b>0.025</b>
Urinary bladder carcinoma	13(3.3)	4(2.0)	9(4.7)	0.144
Prostatic cancer	4(1.0)	0(0.0)	4(2.1)	0.999
Benign prostatic hyperplasia	29(7.4)	10(5.0)	19(9.9)	0.065
Urolithiasis stone	43(10.9)	15(7.4)	28(14.6)	<b>0.025</b>
fragmentation				
Urological surgery	58(14.7)	21(10.4)	37(19.3)	<b>0.014</b>
Hospitalization (within 6 months)	80(20.3)	26(12.8)	54(28.1)	<b>&lt;0.001</b>
ICU hospitalization (within 6 months)	11(2.8)	4(2.0)	7(3.6)	0.323
Indwelling urinary catheter operation (within 6 months)	54(13.7)	19(9.4)	35(18.2)	<b>0.002</b>
Antibiotic use (within 6 months)	110(27.9)	41(20.3)	69(35.9)	<b>&lt;0.001</b>
Second-generation cephalosporins	20(5.1)	9(4.5)	11(5.7)	0.566
Third-generation cephalosporins	67(17.0)	24(11.9)	43(22.4)	<b>0.006</b>
Quinolone antibiotics	35(8.9)	17(8.4)	18(9.4)	0.492

**Table 3: Multivariate analysis of the risk factors in ESBL-positive patients**

	OR	95% confidence interval	P value
Parenchymal tumor	1.801	0.882–3.678	0.107
Urolithiasis stone fragmentation	2.450	1.342–4.473	<b>0.004</b>
Urological surgery	3.102	1.534–6.270	<b>0.002</b>
Indwelling urinary catheter operation (within 6 months)	2.059	1.025–4.133	<b>0.042</b>
Hospitalization (within 6 months )	2.127	1.207–3.748	<b>0.009</b>
Third-generation cephalosporins	1.903	1.069–3.389	<b>0.029</b>

**3.4 Drug Resistance Analysis**

The drug resistance analysis of ESBL-EC revealed revealed that the sensitivity of carbapenems, including imipenem, meropenem, and ertapenem; amikacin; cefotetan; piperacillin/tazobactam; nitrofurantoin; and cefoperazone/sulbactam was 100%, 100%, 96.6%, 95.3%, 87.9%, and 76.5%, respectively. The antibiotic resistance rates of ampicillin, ceftriaxone, cefixime, penicillin

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignment Supérieur (ABES).

cefuroxime, levofloxacin, and ciprofloxacin were 100%, 100%, 100%, 98.7%, 76.5%, 73.8%, and 77.8%, respectively (see Table 4).

**Table 4: Analysis of resistance in ESBL-positive patients**

Antibiotics	Resistance (%)	Sensitivity (%)	Intermediate (%)
Ampicillin	100	0	0
Ampicillin/sulbactam	65.1	23.5	11.4
Piperacillin/tazobactam	2.7	95.3	2
Mezlocillin	98.7	1.3	0
Cefuroxime	76.5	23.5	0
Cefoperazone / Sulbactam	12.1	76.5	11.4
Cefotetan	0	96.6	3.4
Ceftazidime	44.3	52.3	4.6
Ceftriaxone	100	0	0
Cefminox	100	0	0
Cefepime	41.6	58.4	0
Cefotaxime	64.4	35.6	0
Aztreonam	66.4	33.6	0
Imipenem	0	100	0
Meropenem	0	100	0
Ertapenem	0	100	0
Gentamicin	43.6	56.4	0
Tobramycin	16.1	64.4	19.5
Amikacin	0	100	0
Levofloxacin	73.8	10.7	15.5
Ciprofloxacin	77.8	18.8	3.4
Furadantin	3.4	87.9	8.7
Bactrim	62.4	37.6	0

## 4 Discussion

UTI caused by ESBL-EC, characterized by bacterial resistance and recurrence, is one of the most common infections in the community; it has a high treatment difficulty. ESBL-EC can be genetically encoded to produce ESBL, and degraded  $\beta$ -lactamase antibiotics widely used in the clinic, making the bacteria resistant to these antibiotics [3]. Furthermore, it is also possible to spread drug-resistant genes to other bacteria by transfer nature plasmid vectors or by mechanisms such as homologous recombination, leading to multidrug resistance [4]. Over the past 20 years, ESBL-EC has widely spread worldwide and is no longer restricted to infections in hospital wards, and the prevalence of CAUTIs caused by ESBL-EC is continuously increasing [1, 2].

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Epidemiological studies have shown marked differences in the transmission of ESBL-EC, mainly because ESBL-EC has a high genetic diversity and diverse resistant strains may dominate in different regions and populations [1]. To understand the spread and differences of CAUTIs caused by ESBL-EC in various regions in the last two decades, we referred to a large and reliable literature. Two studies in China reported the prevalence of ESBL-EC in CAUTIs [7, 8]. In 2021, a prospective multicenter study in East China [7] reported the prevalence of ESBL-EC in communities in detail, comprising 1760 UTI cases from 19 hospitals; the detection rate of ESBL *Enterobacteriaceae* was 37.2%. The detection rate of community-acquired ESBL-EC cases was 22% in a retrospective study from Tongren Hospital, Beijing, China [8]. A similar pattern has been reported in several European countries, with a study from the Glasgow region of Scotland, UK, published in 2011 indicating a detection rate of ESBL *Enterobacteriaceae* of 7.5% in urine samples [9]. The detection rate of ESBL-EC in CAUTIs increased from 0.47% in 2000 to 1.7% in 2014 in Spain [10]. A 9-year retrospective Australian study revealed a 44% increase in the proportion of ESBL-EC in individuals with UTIs caused by *E. coli* from 4.6% in 2006 to 6.6% in 2014 [11]. The prevalence of ESBL-EC has also been reported in countries in West Asia, with a report from Turkey in 2019 revealing a 50.5% detection rate of ESBL-EC in UTIs [12]. In 2018, a two-center cross-sectional study from Amman in Jordan reported a detection rate as high as 62% [13]. A multicenter study from North America reported a 3.9% detection rate of ESBL-EC in patients with community-associated infections [14], and another study from California reported a 5.9% detection rate in patients with UTIs [15]. In the present study, we reviewed all cases of CAUTIs caused by *E. coli* in the Chongqing region over the past 5 years and found that the detection rate of ESBL-EC was 48.7%, which was higher than that in East China and Beijing; much higher than that in the United Kingdom, Spain, Australia, and the United States; and lower than that in Turkey and Jordan.

The high detection rate of ESBL-EC in the community may be associated with the clinical characteristics of the local infected population and the previous healthcare and antibiotic usage patterns of patients. In the present study, the proportion of ESBL-positive female patients was 74%, which was much higher than that of male patients. This finding is consistent with those of two reports from East China and Beijing, wherein the number of ESBL-positive female patients was more than 80% [7, 8]. Moreover, women are more susceptible to UTIs for reasons associated with the physiological anatomy and estrogen levels of women [16, 17]. In terms of anatomy, the female urethra is relatively shorter than that of males and closer to the anus, increasing the chance of bacterial migration from the intestine to the urinary tract. Postmenopausal women are more susceptible to ascending UTIs due to changes in the urinary and vaginal microbiota because of reduced estrogen levels, with blooms of enterobacterial flora [17]. Oral or topical estrogen preparations are used to prevent recurrent UTIs in postmenopausal women [17, 18]. In the present study, most women were infected with CAUTIs caused by ESBL-EC, and the patients' age was mainly over 60 years old, which is consistent with the fact that menopausal women are more susceptible to UTIs.

In the present study, the mean age of the patients was (64 ± 13) years, and 62.0% (119/192) of the patients were aged 60 years and older. The vast majority of patients had underlying comorbidities, including diabetes, hypertension, urinary stones, parenchymal tumors, and others. Regarding the risk

factors, 19.3% of patients had a history of urologic surgery, 18.2% had an indwelling urinary catheter inserted within 6 months, 28.1% were hospitalized within 6 months, and 35.9% used antibiotics within 6 months.

Univariate analysis revealed that parenchymal tumor, history of urolithiasis stone fragmentation, history of urological surgery, hospitalization within 6 months, indwelling urinary catheter insertion within 6 months, and antibiotic use (mainly third-generation cephalosporins) within 6 months were factors significantly associated with CAUTIs caused by ESBL-EC ( $P < 0.05$ ). Multivariate analysis revealed that a history of urolithiasis stone fragmentation, urological surgery, indwelling urinary catheter insertion within 6 months, hospitalization within 6 months, and use of third-generation cephalosporins were independent risk factors for CAUTIs caused by ESBL-EC. Although these findings are similar to those of previous studies [7, 8, 11-14, 19], there are still some differences. Furthermore, age is one of the possible risk factors [11, 12], and ESBL-positive patients were older than ESBL-negative patients in our study; however, the age difference was not statistically significant in the regression analysis ( $P = 0.088$ ). Prostatic hyperplasia is one of the possible risk factors [7], and more patients with prostatic hyperplasia were ESBL-positive than ESBL-negative; however, the difference was not significant in the regression analysis ( $P = 0.065$ ). Clinically, patients with prostatic hyperplasia present with urinary tract obstruction and urine retention and need more frequent catheterization maneuvers, which undoubtedly increases the risk of ESBL-EC infection. Nonetheless, our findings did not include prostatic hyperplasia as one of the independent risk factors, possibly due to the low sample size of male patients and a smaller number of patients with prostatic hyperplasia. This led to some deviation in the statistical results.

The most difficult part of UTI treatment is the increase in bacterial resistance, and the multidrug resistance of ESBL-EC makes the choice of therapeutic agents narrower and limited, in turn, increases the difficulty of treatment. In the present study, we statistically evaluated the results of susceptibility testing in 192 ESBL-positive patients. The results showed that carbapenems, including imipenem, meropenem, and ertapenem, had very strong antimicrobial activity in vitro, with 100% sensitivity. Aminoglycoside antimicrobials showed a wide variation in the antimicrobial activity; the sensitivity of amikacin was excellent, reaching 100%, and that of gentamicin and tobramycin was 64.4% and 54.4%, respectively. Nitrofurantoin, a nitrofur, had a sensitivity of 87.9%. The sensitivity of piperacillin/tazobactam was 95.3%.

The treatment guidelines on multidrug-resistant bacteria issued by the Infectious Disease Society of America in 2022 indicated that carbapenems have strong antibacterial activity against ESBL-producing *Enterobacteriaceae* and can be the first choice of treatment for pyelonephritis and complicated UTI caused by ESBL-producing *Enterobacteriaceae* [5]. In addition, piperacillin/tazobactam, a commonly used empirical therapeutic agent, demonstrated good antibacterial activity against multiple ESBL-producing *Enterobacteriaceae* [20]. However, compared with the in vitro efficacy of carbapenems, piperacillin/tazobactam is slightly less effective [5], which is consistent with the results of our study. It is important to note that the prevalence of carbapenem-resistant *Enterobacteriaceae* is also constantly increasing [21] and that repeated carbapenem use is a major contributing factor to the increasing prevalence of carbapenem-resistant

*Enterobacteriaceae* [22]. Therefore, we preferentially use piperacillin/tazobactam for some patients with CAUTIs caused by ESBL-ECs who are less symptomatic, thus reducing the frequency of carbapenem use.

Currently, the commonly used cephalosporins for the treatment of infections are not very effective in treating infections caused by ESBL-EC. In the present study, only the second-generation cephalosporin cefotetan had a high sensitivity (96.6%); third-generation cephalosporins have developed obvious resistance, and the resistance for ceftriaxone and cefixime reached 100%. Combined with the risk factor analysis in this study, the use of third-generation cephalosporins is an independent risk factor for CAUTIs caused by ESBL-EC, and we assume that there may be a situation of transitional third-generation cephalosporin use in this region and that the widespread use of third-generation cephalosporins will induce the emergence of new ESBL strains. Thus, the use of third-generation cephalosporins should be reduced in response to community-acquired infections, particularly CAUTIs caused by ESBL-EC to avoid inducing more ESBL-producing

**5 Conclusions**

The positive detection rate of CAUTIs caused by ESBL-EC in this study was high; history of urolithiasis stone fragmentation, urological surgery, indwelling urinary catheter insertion within 6 months, hospitalization within 6 months, and use of third-generation cephalosporins were independent risk factors for CAUTIs caused by ESBL-EC. The susceptibility profile suggested significant resistance to penicillins, cephalosporins, and quinolones; however, carbapenems and amikacin showed 100% sensitivity.

**Ethical Approval**

This study was approved by the Ethics Commission of The People's Hospital of Dazu District.

**Authors' contributions**

YLZ and BLL conceived the study. HLL and YLZ collected the data. LHL and JW analyzed the data. BLL and YLZ wrote this article. JW and HX revised it. HX supervised study conduct. All the authors have read and approved the final version of this manuscript.

**Funding**

The study was supported by *The Chongqing Key Specialty Construction of Public Health*.

**Declaration of Competing Interest**

The authors declare that there are no competing interests.

**Acknowledgments**

We acknowledge all health-care workers involved in the diagnosis and treatment of patients in Dazu

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignment Supérieur (ABES).



Chongqing. We thank the clinical laboratory department from The People's Hospital of Dazu District, and We thank Medjaden Inc. for its assistance in the preparation of this manuscript

## Availability of Data and Materials

The data can get from Jing Wu by email: 2861914532@qq.com

## References

- [1] Karlowsky JA, Lob SH, DeRyke CA, et al. Prevalence of ESBL non-CRE *Escherichia coli* and *Klebsiella pneumoniae* among clinical isolates collected by the SMART global surveillance programme from 2015 to 2019. *Int J Antimicrob Agents*. 2022;59(3):106535. doi:10.1016/j.ijantimicag.2022.106535
- [2] Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. *Lancet Infect Dis*. 2008;8(3):159-166. doi:10.1016/S1473-3099(08)70041-0
- [3] Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. *Clin Microbiol Rev*. 2001;14(4):933-951. doi:10.1128/CMR.14.4.933-951.2001
- [4] Shah AA, Hasan F, Ahmed S, Hameed A. Extended-spectrum beta-lactamases (ESBLs): characterization, epidemiology and detection. *Crit Rev Microbiol*. 2004;30(1):25-32. doi:10.1080/10408410490266429
- [5] Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum  $\beta$ -lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and *Pseudomonas aeruginosa* with Difficult-to-Treat Resistance (DTR-P. *aeruginosa*). *Clin Infect Dis*. 2022;75(2):187-212. doi:10.1093/cid/ciac268
- [6] CLSI Performance standards for antimicrobial susceptibility testing. CLSI Supplement M100. 28th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2018.
- [7] J. Quan, H. Dai, W. Liao et al., Etiology and prevalence of ESBLs in adult community-onset urinary tract infections in East China: A prospective multicenter study, *Journal of Infection*, <https://doi.org/10.1016/j.jinf.2021.06.004>
- [8] Ludong Q, Shan C, Lihui M. Risk factors of urinary tract infection caused by extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli* [J]. *Chinese Journal of Nosocomiology*, 2011, 21(02):247-249.
- [9] Khanna N, Boyes J, Lansdell PM, Hamouda A, Amyes SG. Molecular epidemiology and antimicrobial resistance pattern of extended-spectrum- $\beta$ -lactamase-producing Enterobacteriaceae in Glasgow, Scotland. *J Antimicrob Chemother*. 2012;67(3):573-577. doi:10.1093/jac/dkr523
- [10] Calbo E, Román V, Xercavins M, et al. Risk factors for community-onset urinary tract infections due to *Escherichia coli* harbouring extended-spectrum beta-lactamases. *J Antimicrob Chemother*. 2006;57(4):780-783. doi:10.1093/jac/dkl035
- [11] Toner L, Papa N, Aliyu SH, Dev H, Lawrentschuk N, Al-Hayek S. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospital urinary tract infections: incidence and antibiotic susceptibility profile over 9 years. *World J Urol*. 2016;34(7):1031-1037. doi:10.1007/s00345-015-

1  
2  
3  
4 318 1718-x  
5  
6 319 [12] Tüzün T, Sayın Kutlu S, Kutlu M, Kaleli İ. Risk factors for community-onset urinary tract  
7 320 infections caused by extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli*. *Turk J Med Sci*.  
8 321 2019;49(4):1206-1211. Published 2019 Aug 8. doi:10.3906/sag-1902-24  
9  
10 322 [13] Al-Jamei SA, Albsoul AY, Bakri FG, Al-Bakri AG. Extended-spectrum  $\beta$ -lactamase producing  
11 323 *E. coli* in urinary tract infections: A two-center, cross-sectional study of prevalence, genotypes and  
12 324 risk factors in Amman, Jordan. *J Infect Public Health*. 2019;12(1):21-25.  
13 325 doi:10.1016/j.jiph.2018.07.011  
14  
15 326 [14] Doi Y, Park YS, Rivera JI, et al. Community-associated extended-spectrum be- ta-lactamase-  
16 327 producing *Escherichia coli* infection in the United States. *Clin Infect Dis* 2013;56:641–8.  
17 328 [15] Frazee BW, Trivedi T, Montgomery M, Petrovic DF, Yamaji R, Riley L. Emergency  
18 329 Department Urinary Tract Infections Caused by Extended-Spectrum  $\beta$ -Lactamase-Producing  
19 330 Enterobacteriaceae: Many Patients Have No Identifiable Risk Factor and Discordant Empiric  
20 331 Therapy Is Common. *Ann Emerg Med*. 2018;72(4):449-456.  
21 332 doi:10.1016/j.annemergmed.2018.05.006  
22  
23 333 [16] Geerlings SE. Clinical Presentations and Epidemiology of Urinary Tract Infections. *Microbiol*  
24 334 *Spectr*. 2016;4(5):10.1128/microbiolspec.UTI-0002-2012. doi:10.1128/microbiolspec.UTI-0002-  
25 335 2012  
26  
27 336 [17] Stamm WE. Estrogens and urinary-tract infection. *J Infect Dis*. 2007;195(5):623-624.  
28 337 doi:10.1086/511526  
29  
30 338 [18] Perrotta C, Aznar M, Mejia R, Albert X, Ng CW. Oestrogens for preventing recurrent urinary  
31 339 tract infection in postmenopausal women. *Cochrane Database Syst Rev*. 2008;(2):CD005131.  
32 340 Published 2008 Apr 16. doi:10.1002/14651858.CD005131.pub2  
33  
34 341 [19] Søgaard M, Heide-Jørgensen U, Vandenbroucke JP, Schönheyder HC, Vandenbroucke-Grauls  
35 342 CMJE. Risk factors for extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli* urinary tract  
36 343 infection in the community in Denmark: a case-control study. *Clin Microbiol Infect*.  
37 344 2017;23(12):952-960. doi:10.1016/j.cmi.2017.03.026  
38  
39 345 [20] Bush K, Macalintal C, Rasmussen BA, Lee VJ, Yang Y. Kinetic interactions of tazobactam  
40 346 with beta-lactamases from all major structural classes. *Antimicrob Agents Chemother*.  
41 347 1993;37(4):851-858. doi:10.1128/AAC.37.4.851  
42  
43 348 [21] Zhang R, Liu L, Zhou H, et al. Nationwide Surveillance of Clinical Carbapenem-resistant  
44 349 Enterobacteriaceae (CRE) Strains in China. *EBioMedicine*. 2017;19:98-106.  
45 350 doi:10.1016/j.ebiom.2017.04.032  
46  
47 351 [22] Sun Q, Yang X, Huang Y, et al. Risk factors and clinical impact associated with infections  
48 352 caused by different types of carbapenem-resistant *Klebsiella pneumoniae* in China: A clinical study  
49 353 from 2014 to 2017. *J Infect*. 2022;85(4):436-480. doi:10.1016/j.jinf.2022.05.045  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



# BMJ Open

## Risk factors and drug resistance of adult Community onset urinary tract infections caused by Escherichia coli-producing extended spectrum $\beta$ -lactamase in the Chongqing region, China: A retrospective case-control study

Journal:	BMJ Open
Manuscript ID	bmjopen-2024-090665.R1
Article Type:	Original research
Date Submitted by the Author:	10-Sep-2024
Complete List of Authors:	Zhou, yan-ling; The People's Hospital of Dazu Chongqing, Department of Infectious Disease Long, Biao-li; The People's Hospital of Dazu Chongqing, Department of Infectious Disease Liu, He-Lei; The People's Hospital of Dazu Chongqing, Department of Infectious Disease Wu, Jing; The People's Hospital of Dazu Chongqing, Department of Infectious Disease Xia, Hong; The People's Hospital of Dazu Chongqing, Department of Infectious Disease
<b>Primary Subject Heading</b>:	Public health
Secondary Subject Heading:	Urology, Epidemiology
Keywords:	Urinary tract infections < UROLOGY, PUBLIC HEALTH, Adult urology < UROLOGY, Case-Control Studies, Community Participation

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

# Risk factors and drug resistance of adult Community onset urinary tract infections caused by *Escherichia coli*-producing extended spectrum $\beta$ -lactamase in the Chongqing region, China: A retrospective case-control study

Yan-ling Zhou<sup>1\*</sup>, Biao-li Long<sup>1\*</sup>, He-lei Liu<sup>1</sup>, Jing Wu<sup>1#</sup>, Hong Xia<sup>1#</sup>

<sup>1</sup>Department of Infectious Disease, The People's Hospital of Dazu Chongqing, Chongqing 402360, China

\*Authors contributed equally

#Correspondence: Jing Wu 2861914532@qq.com ; Hong Xia HongXiaChongqing@163.com

## ABSTRACT:

**Objective:** To evaluate the prevalence, resistance, and risk factors of Community onset urinary tract infections (COUTIs) caused by extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli* (ESBL-EC) for providing a basis for the selection of clinical therapeutic agents.

**Design:** retrospective case-control study.

**Setting:** The Affiliated Dazu Hospital of Chongqing Medical University (as known as The People's Hospital of Dazu Chongqing), a 1000-bed tertiary hospital, in China.

**Data and participants:** This study encompassed adult patients diagnosed with community-acquired urinary tract infections caused by *Escherichia coli* between May 2017 and December 2022, with exclusion criteria including incomplete clinical data, disagreement to participate in the study, hospitalization duration exceeding 48 hours prior to confirmation of diagnosis, and prior history of urinary tract infection caused by *Escherichia coli*.

**Outcome measures:** The risk factors for COUTIs caused by ESBL-EC were evaluated using a case-control design, defining patients who were diagnosed with UTIs and had an ESBL-positive urine culture as the case group and patients who were diagnosed with UTIs and had an ESBL-negative urine culture as the control group. Analyzing Drug Resistance of ESBL-EC.

**Results:** In total, 394 cases of COUTIs caused by *E. coli* were included; 192 cases were ESBL-positive, with a detection rate of 48.7% (192/394). Parenchymal tumor, history of urolithiasis stone fragmentation, history of urological surgery, hospitalization within 6 months, indwelling catheter outside hospital, and antibiotic use (mainly third-generation cephalosporins) were the factors significantly associated with COUTIs caused by ESBL-EC ( $P < 0.05$ ) through logistic regression for univariate analysis. Multivariate analysis revealed that a history of urolithiasis stone fragmentation (OR=2.450; 95%CI: 1.342-4.473;  $P=0.004$ ), urological surgery (OR=3.102; 95%CI: 1.534-6.270;

1  
2  
3  
4  
5 33 P=0.002), indwelling catheter outside hospital (OR=2.059; 95%CI: 1.025-4.133; P=0.042),  
6 34 hospitalization within 6 months (OR=2.127; 95%CI: 1.207-3.748; P=0.009), and use of third-  
7 35 generation cephalosporins (OR=1.903; 95%CI: 1.069-3.389; P=0.029) were the independent risk  
8 36 factors for COUTIs caused by ESBL-EC. Analysis of resistance in ESBL-EC revealed that the  
9 37 sensitivity of carbapenems, including imipenem, meropenem, and ertapenem; amikacin; cefotetan;  
10 38 piperacillin/tazobactam; nitrofurantoin; and cefoperazone/sulbactam was 100%, 100%, 96.6%,  
11 39 95.3%, 87.9%, and 76.5%, respectively. Penicillins, cephalosporins, and quinolones were associated  
12 40 with higher antibiotic resistance rates.

13  
14  
15  
16 41 **Conclusions:** Our results revealed high ESBL-EC detection rates. COUTIs caused by ESBL-EC are  
17 42 more likely to occur in patients with parenchymal tumor, a history of urolithiasis stone  
18 43 fragmentation, a history of urological surgery, hospitalization within 6 months, indwelling catheter  
19 44 outside hospital, and use of third-generation cephalosporins. These patients were highly resistant to  
20 45 penicillins, cephalosporins, and quinolones.

21  
22  
23 46 **Key Words:** Drug Resistance; Community onset urinary tract infections; *Escherichia Coli*-  
24 47 producing Extended Spectrum  $\beta$ -Lactamase; Adult

25  
26  
27 48 **Strengths and limitations of this study**

28  
29 49 The study focused on community-acquired UTIs in patients, 62% of whom were  $\geq 60$  years.  
30 50 Results are applicable to elderly community dwellers.

31  
32 51  
33 52 Using a case-control design, this study examined factors associated with ESBL-EC UTIs, including  
34 53 comorbidities, surgical history, recent antibiotic usage, and indwelling catheter outside hospital.

35 54  
36 55 The study utilized the the double-disk diffusion method for confirmation of bacterial phenotypes,  
37 56 without conducting genetic sequencing at the molecular level.

38 57  
39 58 This retrospective study relies on existing data, potentially limited by incompleteness, bias, and  
40 59 confounding factors.

41  
42  
43  
44  
45 60 **1 Introduction**

46  
47  
48 61 Urinary tract infections (UTIs) are characterized by high incidence rates, frequent recurrence, a  
49 62 predisposition among certain populations, and bacterial resistance, among other notable features, is  
50 63 one of the most common infections in the community, with urinary-derived *Escherichia coli* being  
51 64 the most predominant pathogenic bacteria. *E. coli* has shown more complex changes in drug  
52 65 resistance, more rapid geographic variation, and a faster transmission rate with the widespread use of  
53 66 antimicrobials. The establishment of long-term surveillance and analysis of drug resistance in *E. coli*  
54 67 are being focused on globally to find a faster treatment method for *E. coli* infections and control the  
55 68 epidemic of novel drug-resistant strains [1, 2].

The current worldwide prevalence of extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli* (ESBL-EC) in the community is increasing, causing a significant issue in clinical diagnosis and treatment [1, 2]. Laboratory studies have reported that ESBL-producing *Enterobacteriaceae* can produce several  $\beta$ -lactamases to hydrolyze broad-spectrum  $\beta$ -lactamase antibiotics, thus leading to resistance to penicillins and cephalosporins [3]. Moreover, genes encoding ESBL can be transferred in different species of plasmid-mediated *Enterobacteriaceae* [4]; therefore, bacteria carrying ESBL genes usually comprise additional genes or gene mutations that mediate resistance to multiple antibiotics [5].

Reviewing the literature over the past 20 years approximately, we found reports about the genetic and epidemic characteristics, drug resistance patterns, and susceptibility factors of *E. coli* from China, the United States, the United Kingdom, Australia, Spain, Turkey, Jordan, and other countries [6-14]; the results from these studies have been used in the empirical treatment and development of related drugs in the clinic. In China, a well-established surveillance system for drug-resistant bacteria was formed quite late; therefore, relatively few reports about the bacteria are available, and more surveillance data and laboratory studies are still required to help doctors choose the appropriate treatment. Thus, we herein retrospectively analyzed cases of Community onset urinary tract infections (COUTIs) caused by *E. coli* within the past 5 years in the Chongqing region, China, evaluated the drug resistance and clinical characteristics of ESBL-EC and analyzed the risk factors for COUTIs caused by ESBL-EC by performing a case-control study in ESBL-positive and -negative patients.

## 2 Method

### 2.1 Environment and Population

The People's Hospital of Dazu Chongqing, Dazu District, Chongqing, China, is a national tertiary general hospital integrating medical, teaching, scientific research, preventive health care, first aid, and rehabilitation, with a bed capacity of 1000 and receives more than 8000 patients per year. The Dazu district, located in the western part of Chongqing, has a resident population of 8,56,000, and the region has a high degree of population aging, with a large population suffering from common diseases such as diabetes, cardiovascular disease, respiratory disease, and cancer.

### 2.2 Study Design and Materials

We herein retrospectively reviewed patients diagnosed with COUTIs caused by *E. coli* diagnosed from May 2017 to December 2022. We collected data including sex, age, admission time, sample collection time, clinical manifestations, and risk factors (including underlying disease, history of urologic surgery, hospitalization within 6 months, antibiotic use within 6 months, and indwelling catheter outside hospital) through electronic medical records, examination reports, and telephone call back visits.

The risk factors for COUTIs caused by ESBL-EC were evaluated using a case-control design,

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

105 defining patients who were diagnosed with UTIs and had an ESBL-positive urine culture as the case  
106 group and patients who were diagnosed with UTIs and had an ESBL-negative urine culture as the  
107 control group, using logistic regression for univariate analysis. Multivariate analysis was performed  
108 for variables with significant differences ( $P < 0.05$ ).

109 **2.3 Inclusion and Exclusion Criteria**

110 The inclusion criteria were as follows: (1) patients older than 18 years; (2) those with urine  
111 collection done before admission or within 48 h of admission; (3) those with a positive urine culture  
112 with a growth of  $10^5$  CFU/mL; (5) those with a clinical diagnosis of UTI.

113 The exclusion criteria were as follows: (1) Patients with incomplete clinical data; (2) those who did  
114 not agree to provide case information for participation in the study; (3) those who were hospitalized  
115 for more than 48 h before diagnosis; (4) Patients with a history of recurrent urinary tract infections  
116 caused by *Escherichia coli* (only the sample data from the first episode of infection was included).

117 **2.4 Microbiological Methods**

118 The strain identification was conducted using matrix-assisted laser desorption/ionization time-of-  
119 flight mass spectrometry (VITEK® MS IND MALDI TOF, BioMérieux, France). The isolated *E. coli*  
120 were initially screened using the conventional paper chip diffusion method to detect the susceptibility  
121 to broad-spectrum  $\beta$ -lactamase antibiotics. The phenotypic confirmation of ESBL-EC was performed  
122 using the double-disk diffusion method according to the Clinical and Laboratory Standards Institute  
123 performance standards.

124 **2.5 Antimicrobial Susceptibility Testing**

125 The minimum inhibitory concentration was determined according to the Clinical and Laboratory  
126 Standards Institute guidelines [15], and the standard strain *E. coli* ATCC25922 was used as the  
127 control strain. Drugs including, ampicillin, ampicillin/sulbactam, piperacillin/tazobactam,  
128 meloxicillin, cefuroxime, cefoperazone/sulbactam, cefotetan, ceftazidime, ceftriaxone, cefixime,  
129 cefepime, cefotaxime, aztreonam, imipenem, meropenem, ertapenem, gentamicin, tobramycin,  
130 amikacin, levofloxacin, ciprofloxacin, nitrofurantoin, and cotrimoxazole, were tested.

131 **2.6 Statistical Analysis**

132 Analyses were performed using SPSS 26.0 (IBM Corp., Armonk, NY, USA). Count data were  
133 expressed as numbers and percentages, and chi-square tests were performed. Measurements that met  
134 normal distribution were presented as mean  $\pm$  standard deviation and were subjected to a t-test.  
135 Binary logistic regression was used to analyze the risk factors for COUTIs caused by ESBL-EC, and  
136  $P < 0.05$  was considered statistically significant.

137 **3 Results**



### 3.1 Detection Rate

A total of 394 cases diagnosed with COUTIs caused by *E. coli* were included. Among them, 192 cases were ESBL-positive, with a detection rate of 48.7% (192/394).

### 3.2 Clinical Characteristics of ESBL-Positive Patients

Of the 192 ESBL-positive patients, 50 were male, accounting for 26.0% (50/192). The mean patient age was  $64 \pm 13$  years, and 62.0% (119/192) of the patients were aged 60 years and older. The vast majority of patients had underlying comorbidities, including diabetes, hypertension, parenchymal tumors, prostatic hyperplasia, and others.

The main clinical symptoms included urinary tract irritation signs (urinary frequency: 65, urinary urgencies: 56, and odynuria: 49), dysuria (11), hematuria (19), lumbago (28), pain with percussion in the renal area (21), and fever (35); the detailed results are shown in Table 1.

**Table 1: Clinical presentation and proportion of ESBL-positive patients**

Symptoms	Number	Percent(%)
Urinary irritation	urinary frequency	65
	urinary urgency	56
	Odynuria	49
Dysuria	11	5.7
Hematuria	19	9.9
Lumbago	28	14.6
Renal buckle pain	21	10.9
Fever	35	18.2
Chilly	16	8.3
Shiver	6	3.1
Dizzy	12	6.3
Headache	18	9.4
Nausea	11	5.7
Vomit	17	8.9
Belly distention	14	7.3
Diarrhea	2	1.0

### 3.3 Risk Factors

Univariate analysis showed that parenchymal tumor, history of urolithiasis stone fragmentation, history of urological surgery, hospitalization within 6 months, indwelling catheter outside hospital, and antibiotic use (mainly third-generation cephalosporins) within 6 months were factors significantly associated with COUTIs caused by ESBL-EC ( $P < 0.05$ , see Table 2).

Multivariate analysis of these factors revealed that a history of urolithiasis stone fragmentation, urological surgery, indwelling catheter outside hospital, hospitalization within 6 months, and use of



third-generation cephalosporins were independent risk factors for COUTIs caused by ESBL-EC (see Table 3).

**Table 2: Univariate analysis of the risk factors in ESBL-positive patients**

Risk factors	All patients (%)	ESBL-negative (%)	ESBL-positive (%)	P value
Total	394	202(51.3)	192 (48.7)	
Gender (male)	109(27.9)	59(29.2)	50(26.0)	0.483
Advanced age ( $\geq 60$ years)	227(57.6)	108(53.5)	119(62.0)	0.088
Underlying diseases and comorbidity				
Diabetes	161(40.9)	86(42.6)	75(39.1)	0.479
Hypertension	142(36.0)	68(33.7)	74(38.5)	0.314
Parenchymal tumor	43(10.9)	17(8.4)	26(13.5)	<b>0.025</b>
Urinary bladder carcinoma	13(3.3)	4(2.0)	9(4.7)	0.144
Prostatic cancer	4(1.0)	0(0.0)	4(2.1)	0.999
Benign prostatic hyperplasia	29(7.4)	10(5.0)	19(9.9)	0.065
Urolithiasis stone fragmentation	43(10.9)	15(7.4)	28(14.6)	<b>0.025</b>
Urological surgery	58(14.7)	21(10.4)	37(19.3)	<b>0.014</b>
Hospitalization (within 6 months)	80(20.3)	26(12.8)	54(28.1)	<b>&lt;0.001</b>
ICU hospitalization (within 6 months)	11(2.8)	4(2.0)	7(3.6)	0.323
indwelling catheter outside hospital	54(13.7)	19(9.4)	35(18.2)	<b>0.002</b>
Antibiotic use (within 6 months)	110(27.9)	41(20.3)	69(35.9)	<b>&lt;0.001</b>
Second-generation cephalosporins	20(5.1)	9(4.5)	11(5.7)	0.566
Third-generation cephalosporins	67(17.0)	24(11.9)	43(22.4)	<b>0.006</b>
Quinolone antibiotics	35(8.9)	17(8.4)	18(9.4)	0.492

**Table 3: Multivariate analysis of the risk factors in ESBL-positive patients**

	OR	95% confidence interval	P value
Parenchymal tumor	1.801	0.882–3.678	0.107
Urolithiasis stone fragmentation	2.450	1.342–4.473	<b>0.004</b>
Urological surgery	3.102	1.534–6.270	<b>0.002</b>
indwelling catheter outside hospital	2.059	1.025–4.133	<b>0.042</b>

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignment Supérieur (ABES).

Hospitalization (within 6 months )	2.127	1.207–3.748	<b>0.009</b>
Third-generation cephalosporins	1.903	1.069–3.389	<b>0.029</b>

### 3.4 Drug Resistance Analysis

The drug resistance analysis of ESBL-EC revealed that the sensitivity of carbapenems, including imipenem, meropenem, and ertapenem; amikacin; cefotetan; piperacillin/tazobactam; nitrofurantoin; and cefoperazone/sulbactam was 100%, 100%, 96.6%, 95.3%, 87.9%, and 76.5%, respectively. The antibiotic resistance rates of ampicillin, ceftriaxone, cefixime, penicillin cefuroxime, levofloxacin, and ciprofloxacin were 100%, 100%, 100%, 98.7%, 76.5%, 73.8%, and 77.8%, respectively (see Table 4).

**Table 4: Analysis of resistance in ESBL-positive patients**

Antibiotics	Resistance (%)	Sensitivity (%)	Intermediate (%)
Ampicillin	100	0	0
Ampicillin/sulbactam	65.1	23.5	11.4
Piperacillin/tazobactam	2.7	95.3	2
Mezlocillin	98.7	1.3	0
Cefuroxime	76.5	23.5	0
Cefoperazone / Sulbactam	12.1	76.5	11.4
Cefotetan	0	96.6	3.4
Ceftazidime	44.3	52.3	4.6
Ceftriaxone	100	0	0
Cefminox	100	0	0
Cefepime	41.6	58.4	0
Cefotaxime	64.4	35.6	0
Aztreonam	66.4	33.6	0
Imipenem	0	100	0
Meropenem	0	100	0
Ertapenem	0	100	0
Gentamicin	43.6	56.4	0
Tobramycin	16.1	64.4	19.5
Amikacin	0	100	0
Levofloxacin	73.8	10.7	15.5
Ciprofloxacin	77.8	18.8	3.4
Furadantin	3.4	87.9	8.7
trimethoprim/sulfamethoxazole	62.4	37.6	0

## 4 Discussion

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

UTI caused by ESBL-EC, characterized by bacterial resistance and recurrence, is one of the most common infections in the community; it has a high treatment difficulty. ESBL-EC can be genetically encoded to produce ESBL, and degraded  $\beta$ -lactamase antibiotics widely used in the clinic, making the bacteria resistant to these antibiotics [3]. Furthermore, it is also possible to spread drug-resistant genes to other bacteria by transfer nature plasmid vectors or by mechanisms such as homologous recombination, leading to multidrug resistance [4]. Over the past 20 years, ESBL-EC has widely spread worldwide and is no longer restricted to infections in hospital wards, and the prevalence of COUTIs caused by ESBL-EC is continuously increasing [1, 2].

Epidemiological studies have shown marked differences in the transmission of ESBL-EC, mainly because ESBL-EC has a high genetic diversity and diverse resistant strains may dominate in different regions and populations [1]. To understand the spread and differences of COUTIs caused by ESBL-EC in various regions in the last two decades, we referred to a large and reliable literature. Two studies in China reported the prevalence of ESBL-EC in COUTIs [6, 7]. In 2021, a prospective multicenter study in East China [6] reported the prevalence of ESBL-EC in communities in detail, comprising 1760 UTI cases from 19 hospitals; the detection rate of ESBL *Enterobacteriaceae* was 37.2%. The detection rate of community-acquired ESBL-EC cases was 22% in a retrospective study from Tongren Hospital, Beijing, China [7]. A similar pattern has been reported in several European countries, with a study from the Glasgow region of Scotland, UK, published in 2011 indicating a detection rate of ESBL *Enterobacteriaceae* of 7.5% in urine samples [8]. The detection rate of ESBL-EC in COUTIs increased from 0.47% in 2000 to 1.7% in 2014 in Spain [9]. A 9-year retrospective Australian study revealed a 44% increase in the proportion of ESBL-EC in individuals with UTIs caused by *E. coli* from 4.6% in 2006 to 6.6% in 2014 [10]. The prevalence of ESBL-EC has also been reported in countries in West Asia, with a report from Turkey in 2019 revealing a 50.5% detection rate of ESBL-EC in UTIs [11]. In 2018, a two-center cross-sectional study from Amman in Jordan reported a detection rate as high as 62% [12]. A multicenter study from North America reported a 3.9% detection rate of ESBL-EC in patients with community-associated infections [13], and another study from California reported a 5.9% detection rate in patients with UTIs [14]. In the present study, we reviewed all cases of COUTIs caused by *E. coli* in the Chongqing region over the past 5 years and found that the detection rate of ESBL-EC was 48.7%, which was higher than that in East China and Beijing; much higher than that in the United Kingdom, Spain, Australia, and the United States; and lower than that in Turkey and Jordan.

The high detection rate of ESBL-EC in the community may be associated with the clinical characteristics of the local infected population and the previous healthcare and antibiotic usage patterns of patients. In the present study, the proportion of ESBL-positive female patients was 74%, which was much higher than that of male patients. This finding is consistent with those of two reports from East China and Beijing, wherein the number of ESBL-positive female patients was more than 80% [6, 7]. Moreover, women are more susceptible to UTIs for reasons associated with the physiological anatomy and estrogen levels of women [16, 17]. In terms of anatomy, the female urethra is relatively shorter than that of males and closer to the anus, increasing the chance of bacterial migration from the intestine to the urinary tract. Postmenopausal women are more susceptible to ascending UTIs due to changes in the urinary and vaginal microbiota because of

reduced estrogen levels, with blooms of enterobacterial flora [17]. Oral or topical estrogen preparations are used to prevent recurrent UTIs in postmenopausal women [17, 18]. In the present study, most women were infected with COUTIs caused by ESBL-EC, and the patients' age was mainly over 60 years old, which is consistent with the fact that menopausal women are more susceptible to UTIs.

In the present study, the mean age of the patients was ( $64 \pm 13$ ) years, and 62.0% (119/192) of the patients were aged 60 years and older. The vast majority of patients had underlying comorbidities, including diabetes, hypertension, urinary stones, parenchymal tumors, and others. Regarding the risk factors, 19.3% of patients had a history of urologic surgery, 18.2% had an indwelling catheter outside hospital, 28.1% were hospitalized within 6 months, and 35.9% used antibiotics within 6 months.

Univariate analysis revealed that parenchymal tumor, history of urolithiasis stone fragmentation, history of urological surgery, hospitalization within 6 months, indwelling catheter outside hospital, and antibiotic use (mainly third-generation cephalosporins) within 6 months were factors significantly associated with COUTIs caused by ESBL-EC ( $P < 0.05$ ). Multivariate analysis revealed that a history of urolithiasis stone fragmentation, urological surgery, indwelling catheter outside hospital, hospitalization within 6 months, and use of third-generation cephalosporins were independent risk factors for COUTIs caused by ESBL-EC. Although these findings are similar to those of previous studies [6, 7, 10-13, 19], there are still some differences. Furthermore, age is one of the possible risk factors [10, 11], and ESBL-positive patients were older than ESBL-negative patients in our study; however, the age difference was not statistically significant in the regression analysis ( $P = 0.088$ ). Prostatic hyperplasia is one of the possible risk factors [6], and more patients with prostatic hyperplasia were ESBL-positive than ESBL-negative; however, the difference was not significant in the regression analysis ( $P = 0.065$ ). Clinically, patients with prostatic hyperplasia present with urinary tract obstruction and urine retention and need more frequent catheterization maneuvers, which undoubtedly increases the risk of ESBL-EC infection. Nonetheless, our findings did not include prostatic hyperplasia as one of the independent risk factors, possibly due to the low sample size of male patients and a smaller number of patients with prostatic hyperplasia. This led to some deviation in the statistical results.

The most difficult part of UTI treatment is the increase in bacterial resistance, and the multidrug resistance of ESBL-EC makes the choice of therapeutic agents narrower and limited, in turn, increases the difficulty of treatment. In the present study, we statistically evaluated the results of susceptibility testing in 192 ESBL-positive patients. The results showed that carbapenems, including imipenem, meropenem, and ertapenem, had very strong antimicrobial activity in vitro, with 100% sensitivity. Aminoglycoside antimicrobials showed a wide variation in the antimicrobial activity; the sensitivity of amikacin was excellent, reaching 100%, and that of gentamicin and tobramycin was 64.4% and 54.4%, respectively. Nitrofurantoin, a nitrofur, had a sensitivity of 87.9%. The sensitivity of piperacillin/tazobactam was 95.3%.

The treatment guidelines on multidrug-resistant bacteria issued by the Infectious Disease Society of America in 2022 indicated that carbapenems have strong antibacterial activity against ESBL-

producing *Enterobacteriaceae* and can be the first choice of treatment for pyelonephritis and complicated UTI caused by ESBL-producing *Enterobacteriaceae* [5]. In addition, piperacillin/tazobactam, a commonly used empirical therapeutic agent, demonstrated good antibacterial activity against multiple ESBL-producing *Enterobacteriaceae* [20]. However, compared with the in vitro efficacy of carbapenems, piperacillin/tazobactam is slightly less effective [5], which is consistent with the results of our study. It is important to note that the prevalence of carbapenem-resistant *Enterobacteriaceae* is also constantly increasing [21] and that repeated carbapenem use is a major contributing factor to the increasing prevalence of carbapenem-resistant *Enterobacteriaceae* [22]. Therefore, we preferentially use piperacillin/tazobactam for some patients with COUTIs caused by ESBL-ECs who are less symptomatic, thus reducing the frequency of carbapenem use.

Currently, the commonly used cephalosporins for the treatment of infections are not very effective in treating infections caused by ESBL-EC. In the present study, only the second-generation cephalosporin cefotetan had a high sensitivity (96.6%); third-generation cephalosporins have developed obvious resistance, and the resistance for ceftriaxone and cefixime reached 100%. Combined with the risk factor analysis in this study, the use of third-generation cephalosporins is an independent risk factor for COUTIs caused by ESBL-EC, and we assume that there may be a situation of transitional third-generation cephalosporin use in this region and that the widespread use of third-generation cephalosporins will induce the emergence of new ESBL strains. Thus, the use of third-generation cephalosporins should be reduced in response to community-acquired infections, particularly COUTIs caused by ESBL-EC to avoid inducing more ESBL-producing.

The study has some limitations. Firstly, our investigation focused on patients with COUTIs, excluding those with hospital-acquired urinary tract infections. Therefore, we could not compare the difference of epidemiological data between COUTIs and hospital acquired UTIs. secondly, we only compiled statistics and analyzed the drug resistance in the ESBL-positive group, without comparing the differences in drug resistance between the ESBL-positive and ESBL-negative groups.

**5 Conclusions**

The positive detection rate of COUTIs caused by ESBL-EC in this study was high; history of urolithiasis stone fragmentation, urological surgery, indwelling catheter outside hospital, hospitalization within 6 months, and use of third-generation cephalosporins were independent risk factors for COUTIs caused by ESBL-EC. The susceptibility profile suggested significant resistance to penicillins, cephalosporins, and quinolones; however, carbapenems and amikacin showed 100% sensitivity.

**Ethical Approval**

This study was approved by the Ethics Commission of The People's Hospital of Dazu District (No. 2023LLSC0309).

## Authors' contributions

YLZ and BLL conceived the study. HLL and YLZ collected the data. LHL and JW analyzed the data. BLL and YLZ wrote this article. JW and HX revised it. HX supervised study conduct. All the authors have read and approved the final version of this manuscript. JW are responsible for the overall content (as guarantor).

## Funding

The study was supported by *The First batch of key Disciplines On Public Health in Chongqing (YWBF2022072)*.

## Declaration of Competing Interest

The authors declare that there are no competing interests.

## Acknowledgments

We acknowledge to all members of the public and patients who have shown interest in and participated in this research. We acknowledge all health-care workers involved in the diagnosis and treatment of patients in Dazu Chongqing. We thank the clinical laboratory department from The People's Hospital of Dazu District, and We thank Medjaden Inc. for its assistance in the preparation of this manuscript.

## Patient and Public Involvement

Patients and their guardians were not involved in the design and implementation of our study. Patients were not invited to contribute to the writing or editing of this manuscript. We recruited patients who were willing to participate in this study through various methods, including email, telephone interviews, and face-to-face communication. we plan to write popular science articles based on the findings of this study and disseminate them to patients and the public through official channels of hospitals and regional CDCs, as well as by conducting educational lectures in infectious disease departments.

## Availability of Data and Materials

The data can get from Jing Wu by email: 2861914532@qq.com

## References

- [1] Karlowsky JA, Lob SH, DeRyke CA, et al. Prevalence of ESBL non-CRE Escherichia coli and Klebsiella pneumoniae among clinical isolates collected by the SMART global surveillance programme from 2015 to 2019. *Int J Antimicrob Agents*. 2022;59(3):106535. doi:10.1016/j.ijantimicag.2022.106535
- [2] Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

emerging public-health concern. *Lancet Infect Dis.* 2008;8(3):159-166. doi:10.1016/S1473-3099(08)70041-0

[3] Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. *Clin Microbiol Rev.* 2001;14(4):933-951. doi:10.1128/CMR.14.4.933-951.2001

[4] Shah AA, Hasan F, Ahmed S, Hameed A. Extended-spectrum beta-lactamases (ESbLs): characterization, epidemiology and detection. *Crit Rev Microbiol.* 2004;30(1):25-32. doi:10.1080/10408410490266429

[5] Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum  $\beta$ -lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and *Pseudomonas aeruginosa* with Difficult-to-Treat Resistance (DTR-P. *aeruginosa*). *Clin Infect Dis.* 2022;75(2):187-212. doi:10.1093/cid/ciac268

[6] J. Quan, H. Dai, W. Liao et al., Etiology and prevalence of ESBLs in adult community-onset urinary tract infections in East China: A prospective multicenter study, *Journal of Infection*, <https://doi.org/10.1016/j.jinf.2021.06.004>

[7] Ludong Q, Shan C, Lihui M. Risk factors of urinary tract infection caused by extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli* [J]. *Chinese Journal of Nosocomiology*, 2011, 21(02):247-249.

[8] Khanna N, Boyes J, Lansdell PM, Hamouda A, Amyes SG. Molecular epidemiology and antimicrobial resistance pattern of extended-spectrum- $\beta$ -lactamase-producing Enterobacteriaceae in Glasgow, Scotland. *J Antimicrob Chemother.* 2012;67(3):573-577. doi:10.1093/jac/dkr523

[9] Calbo E, Román V, Xercavins M, et al. Risk factors for community-onset urinary tract infections due to *Escherichia coli* harbouring extended-spectrum beta-lactamases. *J Antimicrob Chemother.* 2006;57(4):780-783. doi:10.1093/jac/dkl035

[10] Toner L, Papa N, Aliyu SH, Dev H, Lawrentschuk N, Al-Hayek S. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospital urinary tract infections: incidence and antibiotic susceptibility profile over 9 years. *World J Urol.* 2016;34(7):1031-1037. doi:10.1007/s00345-015-1718-x

[11] Tüzün T, Sayın Kutlu S, Kutlu M, Kaleli İ. Risk factors for community-onset urinary tract infections caused by extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli*. *Turk J Med Sci.* 2019;49(4):1206-1211. Published 2019 Aug 8. doi:10.3906/sag-1902-24

[12] Al-Jamei SA, Albsoul AY, Bakri FG, Al-Bakri AG. Extended-spectrum  $\beta$ -lactamase producing *E. coli* in urinary tract infections: A two-center, cross-sectional study of prevalence, genotypes and risk factors in Amman, Jordan. *J Infect Public Health.* 2019;12(1):21-25. doi:10.1016/j.jiph.2018.07.011

[13] Doi Y, Park YS, Rivera JJ, et al. Community-associated extended-spectrum beta-lactamase-producing *Escherichia coli* infection in the United States. *Clin Infect Dis* 2013;56:641–8.

[14] Frazee BW, Trivedi T, Montgomery M, Petrovic DF, Yamaji R, Riley L. Emergency Department Urinary Tract Infections Caused by Extended-Spectrum  $\beta$ -Lactamase-Producing Enterobacteriaceae: Many Patients Have No Identifiable Risk Factor and Discordant Empiric Therapy Is Common. *Ann Emerg Med.* 2018;72(4):449-456. doi:10.1016/j.annemergmed.2018.05.006

[15] CLSI Performance standards for antimicrobial susceptibility testing. CLSI Supplement M100.



- 28th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2018.
- [16] Geerlings SE. Clinical Presentations and Epidemiology of Urinary Tract Infections. *Microbiol Spectr*. 2016;4(5):10.1128/microbiolspec.UTI-0002-2012. doi:10.1128/microbiolspec.UTI-0002-2012
- [17] Stamm WE. Estrogens and urinary-tract infection. *J Infect Dis*. 2007;195(5):623-624. doi:10.1086/511526
- [18] Perrotta C, Aznar M, Mejia R, Albert X, Ng CW. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. *Cochrane Database Syst Rev*. 2008;(2):CD005131. Published 2008 Apr 16. doi:10.1002/14651858.CD005131.pub2
- [19] Sogaard M, Heide-Jørgensen U, Vandenbroucke JP, Schønheyder HC, Vandenbroucke-Grauls CMJE. Risk factors for extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli* urinary tract infection in the community in Denmark: a case-control study. *Clin Microbiol Infect*. 2017;23(12):952-960. doi:10.1016/j.cmi.2017.03.026
- [20] Bush K, Macalintal C, Rasmussen BA, Lee VJ, Yang Y. Kinetic interactions of tazobactam with beta-lactamases from all major structural classes. *Antimicrob Agents Chemother*. 1993;37(4):851-858. doi:10.1128/AAC.37.4.851
- [21] Zhang R, Liu L, Zhou H, et al. Nationwide Surveillance of Clinical Carbapenem-resistant Enterobacteriaceae (CRE) Strains in China. *EBioMedicine*. 2017;19:98-106. doi:10.1016/j.ebiom.2017.04.032
- [22] Sun Q, Yang X, Huang Y, et al. Risk factors and clinical impact associated with infections caused by different types of carbapenem-resistant *Klebsiella pneumoniae* in China: A clinical study from 2014 to 2017. *J Infect*. 2022;85(4):436-480. doi:10.1016/j.jinf.2022.05.045

# BMJ Open

## Risk factors and drug resistance of adult Community onset urinary tract infections caused by Escherichia coli-producing extended spectrum $\beta$ -lactamase in the Chongqing region, China: A retrospective case-control study

Journal:	BMJ Open
Manuscript ID	bmjopen-2024-090665.R2
Article Type:	Original research
Date Submitted by the Author:	11-Oct-2024
Complete List of Authors:	Zhou, yan-ling; The People's Hospital of Dazu Chongqing, Department of Infectious Disease Long, Biao-li; The People's Hospital of Dazu Chongqing, Department of Infectious Disease Liu, He-Lei; The People's Hospital of Dazu Chongqing, Department of Infectious Disease Wu, Jing; The People's Hospital of Dazu Chongqing, Department of Infectious Disease Xia, Hong; The People's Hospital of Dazu Chongqing, Department of Infectious Disease
<b>Primary Subject Heading</b>:	Public health
Secondary Subject Heading:	Urology, Epidemiology
Keywords:	Urinary tract infections < UROLOGY, PUBLIC HEALTH, Adult urology < UROLOGY, Case-Control Studies, Community Participation

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

# Risk factors and drug resistance of adult Community onset urinary tract infections caused by *Escherichia coli*-producing extended spectrum $\beta$ -lactamase in the Chongqing region, China: A retrospective case-control study

Yan-ling Zhou<sup>1\*</sup>, Biao-li Long<sup>1\*</sup>, He-lei Liu<sup>1</sup>, Jing Wu<sup>1#</sup>, Hong Xia<sup>1#</sup>

<sup>1</sup>Department of Infectious Disease, The People's Hospital of Dazu Chongqing, Chongqing 402360, China

\*Authors contributed equally

#Correspondence: Jing Wu 2861914532@qq.com ; Hong Xia HongXiaChongqing@163.com

## ABSTRACT:

**Objective:** To evaluate the prevalence, resistance, and risk factors of Community onset urinary tract infections (COUTIs) caused by extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli* (ESBL-EC) for providing a basis for the selection of clinical therapeutic agents.

**Design:** a retrospective case-control study.

**Setting:** The Affiliated Dazu Hospital of Chongqing Medical University (as know as The People's Hospital of Dazu Chongqing), a 1000-bed tertiary hospital in China.

**Data and participants:** This study encompassed adult patients diagnosed with community-acquired urinary tract infections caused by *Escherichia coli* between May 2017 and December 2022, with exclusion criteria including incomplete clinical data, disagreement to participate in the study, hospitalization duration exceeding 48 hours prior to confirmation of diagnosis, and prior history of urinary tract infection caused by *Escherichia coli*.

**Outcome measures:** The risk factors for COUTIs caused by ESBL-EC were evaluated using a case-control design, defining patients who were diagnosed with UTIs and had an ESBL-positive urine culture as the case group and patients who were diagnosed with UTIs and had an ESBL-negative urine culture as the control group. Perform drug susceptibility testing and resistance analysis on isolated ESBL-EC.

**Results:** In total, 394 cases of COUTIs caused by *E. coli* were included; 192 cases were ESBL-positive, with a detection rate of 48.7% (192/394). Parenchymal tumor, history of urolithiasis stone fragmentation, history of urological surgery, hospitalization within 6 months, indwelling catheter outside hospital, and antibiotic use (mainly third-generation cephalosporins) were the factors significantly associated with COUTIs caused by ESBL-EC ( $P < 0.05$ ) through logistic regression for univariate analysis. Multivariate analysis revealed that a history of urolithiasis stone fragmentation

(OR=2.450; 95%CI: 1.342-4.473; P=0.004), urological surgery (OR=3.102; 95%CI: 1.534-6.270; P=0.002), indwelling catheter outside hospital (OR=2.059; 95%CI: 1.025-4.133; P=0.042), hospitalization within 6 months (OR=2.127; 95%CI: 1.207-3.748; P=0.009), and use of third-generation cephalosporins (OR=1.903; 95%CI: 1.069-3.389; P=0.029) were the independent risk factors for COUTIs caused by ESBL-EC. The results of the drug susceptibility testing revealed that ESBL-EC exhibited the highest resistance rates to ampicillin, ceftriaxone, and cefixime, all at 100%. Mezlocillin followed with a resistance rate of 98.7%. On the other hand, ESBL-EC strains displayed the highest sensitivity to carbapenem antibiotics (imipenem, meropenem, ertapenem) and amikacin, all at 100%. Sensitivity rates were also high for cefotetan at 96.6%, piperacillin/tazobactam at 95.3%, and nitrofurantoin at 87.9%.

**Conclusions:** Our results revealed high ESBL-EC detection rates. COUTIs caused by ESBL-EC are more likely to occur in patients with parenchymal tumor, a history of urolithiasis stone fragmentation, a history of urological surgery, hospitalization within 6 months, indwelling catheter outside hospital, and use of third-generation cephalosporins. These patients were highly resistant to penicillins, cephalosporins, and quinolones.

**Key Words:** Drug Resistance; Community onset urinary tract infections; *Escherichia Coli*-producing Extended Spectrum  $\beta$ -Lactamase; Adult

### Strengths and limitations of this study

The study focused on community-acquired UTIs in patients, 62% of whom were  $\geq 60$  years. Results are applicable to elderly community dwellers.

Using a case-control design, this study examined factors associated with ESBL-EC UTIs, including comorbidities, surgical history, recent antibiotic usage, and indwelling catheter outside hospital.

The study utilized the the double-disk diffusion method for confirmation of bacterial phenotypes, without conducting genetic sequencing at the molecular level.

This retrospective study relies on existing data, potentially limited by incompleteness, bias, and confounding factors.

## 1 Introduction

Urinary tract infections (UTIs) are characterized by high incidence rates, frequent recurrence, a predisposition among certain populations, and bacterial resistance, among other notable features, is one of the most common infections in the community, with urinary-derived *Escherichia coli* being the most predominant pathogenic bacteria. *E. coli* has shown more complex changes in drug resistance, more rapid geographic variation, and a faster transmission rate with the widespread use of antimicrobials. The establishment of long-term surveillance and analysis of drug resistance in *E. coli*

are being focused on globally to find a faster treatment method for *E. coli* infections and control the epidemic of novel drug-resistant strains [1, 2].

The current worldwide prevalence of extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli* (ESBL-EC) in the community is increasing, causing a significant issue in clinical diagnosis and treatment [1, 2]. Laboratory studies have reported that ESBL-producing *Enterobacteriaceae* can produce several  $\beta$ -lactamases to hydrolyze broad-spectrum  $\beta$ -lactamase antibiotics, thus leading to resistance to penicillins and cephalosporins [3]. Moreover, genes encoding ESBL can be transferred in different species of plasmid-mediated *Enterobacteriaceae* [4]; therefore, bacteria carrying ESBL genes usually comprise additional genes or gene mutations that mediate resistance to multiple antibiotics [5].

Reviewing the literature over the past 20 years approximately, we found reports about the genetic and epidemic characteristics, drug resistance patterns, and susceptibility factors of *E. coli* from China, the United States, the United Kingdom, Australia, Spain, Turkey, Jordan, and other countries [6-14]; the results from these studies have been used in the empirical treatment and development of related drugs in the clinic. In China, a well-established surveillance system for drug-resistant bacteria was formed quite late; therefore, relatively few reports about the bacteria are available, and more surveillance data and laboratory studies are still required to help doctors choose the appropriate treatment. Thus, we herein retrospectively analyzed cases of Community onset urinary tract infections (COUTIs) caused by *E. coli* within the past 5 years in the Chongqing region, China, evaluated the drug resistance and clinical characteristics of ESBL-EC and analyzed the risk factors for COUTIs caused by ESBL-EC by performing a case-control study in ESBL-positive and -negative patients.

## 2 Method

### 2.1 Environment and Population

The People's Hospital of Dazu Chongqing, Dazu District, Chongqing, China, is a national tertiary general hospital integrating medical, teaching, scientific research, preventive health care, first aid, and rehabilitation, with a bed capacity of 1000 and receives more than 8000 patients per year. The Dazu district, located in the western part of Chongqing, has a resident population of 8,56,000, and the region has a high degree of population aging, with a large population suffering from common diseases such as diabetes, cardiovascular disease, respiratory disease, and cancer.

### 2.2 Study Design and Materials

We herein retrospectively reviewed patients diagnosed with COUTIs caused by *E. coli* diagnosed from May 2017 to December 2022. We collected data including sex, age, admission time, sample collection time, clinical manifestations, and risk factors (including underlying disease, history of urologic surgery, hospitalization within 6 months, antibiotic use within 6 months, and indwelling catheter outside hospital) through electronic medical records, examination reports, and telephone call



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

105 back visits.

106 The risk factors for COUTIs caused by ESBL-EC were evaluated using a case-control design,  
107 defining patients who were diagnosed with UTIs and had an ESBL-positive urine culture as the case  
108 group and patients who were diagnosed with UTIs and had an ESBL-negative urine culture as the  
109 control group, using logistic regression for univariate analysis. Multivariate analysis was performed  
110 for variables with significant differences ( $P < 0.05$ ).

111 **2.3 Inclusion and Exclusion Criteria**

112 The inclusion criteria were as follows: (1) patients older than 18 years; (2) those with urine  
113 collection done before admission or within 48 h of admission; (3) those with a positive urine culture  
114 with a growth of  $10^5$  CFU/mL; (5) those with a clinical diagnosis of UTI.

115 The exclusion criteria were as follows: (1) Patients with incomplete clinical data; (2) those who did  
116 not agree to provide case information for participation in the study; (3) those who were hospitalized  
117 for more than 48 h before diagnosis; (4) Patients with a history of recurrent urinary tract infections  
118 caused by *Escherichia coli* (only the sample data from the first episode of infection was included).

119 **2.4 Microbiological Methods**

120 The strain identification was conducted using matrix-assisted laser desorption/ionization time-of-  
121 flight mass spectrometry (VITEK® MS IND MALDI TOF, BioMérieux, France). The isolated *E. coli*  
122 were initially screened using the conventional paper chip diffusion method to detect the susceptibility  
123 to broad-spectrum  $\beta$ -lactamase antibiotics. The phenotypic confirmation of ESBL-EC was performed  
124 using the double-disk diffusion method according to the Clinical and Laboratory Standards Institute  
125 performance standards.

126 **2.5 Antimicrobial Susceptibility Testing**

127 The minimum inhibitory concentration was determined according to the Clinical and Laboratory  
128 Standards Institute guidelines [15], and the standard strain *E. coli* ATCC25922 was used as the  
129 control strain. Drugs including ampicillin, ampicillin/sulbactam, piperacillin/tazobactam,  
130 meloxicillin, cefuroxime, cefoperazone/sulbactam, cefotetan, ceftazidime, ceftriaxone, cefixime,  
131 cefepime, cefotaxime, aztreonam, imipenem, meropenem, ertapenem, gentamicin, tobramycin,  
132 amikacin, levofloxacin, ciprofloxacin, nitrofurantoin, and cotrimoxazole, were tested.

133 **2.6 Statistical Analysis**

134 Analyses were performed using SPSS 26.0 (IBM Corp., Armonk, NY, USA). Count data were  
135 expressed as numbers and percentages, and chi-square tests were performed. Measurements that met  
136 normal distribution were presented as mean  $\pm$  standard deviation and were subjected to a t-test.  
137 Binary logistic regression was used to analyze the risk factors for COUTIs caused by ESBL-EC, and  
138  $P < 0.05$  was considered statistically significant.



### 3 Results

#### 3.1 Detection Rate

A total of 394 cases diagnosed with COUTIs caused by *E. coli* were included. Among them, 192 cases were ESBL-positive, with a detection rate of 48.7% (192/394).

#### 3.2 Clinical Characteristics of ESBL-Positive Patients

Of the 192 ESBL-positive patients, 50 were male, accounting for 26.0% (50/192). The mean patient age was  $64 \pm 13$  years, and 62.0% (119/192) of the patients were 60 years and older. The vast majority of patients had underlying comorbidities, including diabetes, hypertension, parenchymal tumors, prostatic hyperplasia, and others.

The main clinical symptoms included urinary tract irritation signs (urinary frequency: 65, urinary urgencies: 56, and odynuria: 49), dysuria (11), hematuria (19), lumbago (28), pain with percussion in the renal area (21), and fever (35); the detailed results are shown in Table 1.

**Table 1: Clinical presentation and proportion of ESBL-positive patients**

Symptoms	Number	Percent(%)
Urinary irritation	urinary frequency	65
	urinary urgency	56
	Odynuria	49
Dysuria	11	5.7
Hematuria	19	9.9
Lumbago	28	14.6
Renal buckle pain	21	10.9
Fever	35	18.2
Chilly	16	8.3
Shiver	6	3.1
Dizzy	12	6.3
Headache	18	9.4
Nausea	11	5.7
Vomit	17	8.9
Belly distention	14	7.3
Diarrhea	2	1.0

#### 3.3 Risk Factors

Univariate analysis showed that parenchymal tumor, history of urolithiasis stone fragmentation, history of urological surgery, hospitalization within 6 months, indwelling catheter outside hospital, and antibiotic use (mainly third-generation cephalosporins) within 6 months were factors significantly associated with COUTIs caused by ESBL-EC ( $P < 0.05$ , see Table 2).

Multivariate analysis of these factors revealed that a history of urolithiasis stone fragmentation, urological surgery, indwelling catheter outside hospital, hospitalization within 6 months, and use of third-generation cephalosporins were independent risk factors for COUTIs caused by ESBL-EC (see Table 3).

**Table 2: Univariate analysis of the risk factors in ESBL-positive patients**

Risk factors	All patients (%)	ESBL-negative (%)	ESBL-positive (%)	P value
Total	394	202(51.3)	192 (48.7)	
Gender (male)	109(27.9)	59(29.2)	50(26.0)	0.483
Advanced age ( $\geq 60$ years)	227(57.6)	108(53.5)	119(62.0)	0.088
Underlying diseases and comorbidity				
Diabetes	161(40.9)	86(42.6)	75(39.1)	0.479
Hypertension	142(36.0)	68(33.7)	74(38.5)	0.314
Parenchymal tumor	43(10.9)	17(8.4)	26(13.5)	<b>0.025</b>
Urinary bladder carcinoma	13(3.3)	4(2.0)	9(4.7)	0.144
Prostatic cancer	4(1.0)	0(0.0)	4(2.1)	0.999
Benign prostatic hyperplasia	29(7.4)	10(5.0)	19(9.9)	0.065
Urolithiasis stone fragmentation	43(10.9)	15(7.4)	28(14.6)	<b>0.025</b>
Urological surgery	58(14.7)	21(10.4)	37(19.3)	<b>0.014</b>
Hospitalization (within 6 months)	80(20.3)	26(12.8)	54(28.1)	<b>&lt;0.001</b>
ICU hospitalization (within 6 months)	11(2.8)	4(2.0)	7(3.6)	0.323
indwelling catheter outside hospital	54(13.7)	19(9.4)	35(18.2)	<b>0.002</b>
Antibiotic use (within 6 months)	110(27.9)	41(20.3)	69(35.9)	<b>&lt;0.001</b>
Second-generation cephalosporins	20(5.1)	9(4.5)	11(5.7)	0.566
Third-generation cephalosporins	67(17.0)	24(11.9)	43(22.4)	<b>0.006</b>
Quinolone antibiotics	35(8.9)	17(8.4)	18(9.4)	0.492

**Table 3: Multivariate analysis of the risk factors in ESBL-positive patients**

	OR	95% confidence interval	P value
Parenchymal tumor	1.801	0.882–3.678	0.107
Urolithiasis stone fragmentation	2.450	1.342–4.473	<b>0.004</b>
Urological surgery	3.102	1.534–6.270	<b>0.002</b>

indwelling catheter outside hospital	2.059	1.025–4.133	<b>0.042</b>
Hospitalization (within 6 months )	2.127	1.207–3.748	<b>0.009</b>
Third-generation cephalosporins	1.903	1.069–3.389	<b>0.029</b>

### 3.4 Drug Resistance Analysis

The results of drug sensitivity testing revealed high resistance rates of ESBL-EC to the penicillin drugs ampicillin and mezlocillin, with resistance rates of 100% and 98.7%, respectively. There was considerable variation in the resistance of ESBL-EC to cephalosporins. Specifically, the resistance rates to ceftriaxone and cefixime both reached 100%, whereas the resistance rate to cefotetan was 0%, with a sensitivity rate of 96.6%. This indicates the potential value of cefotetan in the treatment of infections caused by ESBL-EC.

ESBL-EC showed the highest sensitivity to carbapenems, with sensitivity rates of 100% for imipenem, meropenem, and ertapenem, following the carbapenems, cefotetan, piperacillin/tazobactam, and nitrofurantoin exhibited sensitivity rates of 96.6%, 95.3%, and 87.9%, respectively (see Table 4).

**Table 4: Analysis of resistance in ESBL-positive patients**

Antibiotics	Resistance (%)	Sensitivity (%)	Intermediate (%)
Ampicillin	100	0	0
Ampicillin/sulbactam	65.1	23.5	11.4
Piperacillin/tazobactam	2.7	95.3	2
Mezlocillin	98.7	1.3	0
Cefuroxime	76.5	23.5	0
Cefoperazone / Sulbactam	12.1	76.5	11.4
Cefotetan	0	96.6	3.4
Ceftazidime	44.3	52.3	4.6
Ceftriaxone	100	0	0
Cefixime	100	0	0
Cefepime	41.6	58.4	0
Cefotaxime	64.4	35.6	0
Aztreonam	66.4	33.6	0
Imipenem	0	100	0
Meropenem	0	100	0
Ertapenem	0	100	0
Gentamicin	43.6	56.4	0
Tobramycin	16.1	64.4	19.5
Amikacin	0	100	0
Levofloxacin	73.8	10.7	15.5

Ciprofloxacin	77.8	18.8	3.4
Furadantin	3.4	87.9	8.7
trimethoprim/sulfamethoxazole	62.4	37.6	0

#### 4 Discussion

UTI caused by ESBL-EC, characterized by bacterial resistance and recurrence, is one of the most common infections in the community; it has a high treatment difficulty. ESBL-EC can be genetically encoded to produce ESBL, and degraded  $\beta$ -lactamase antibiotics are widely used in the clinic, making the bacteria resistant to these antibiotics [3]. Furthermore, it is also possible to spread drug-resistant genes to other bacteria by transfer nature plasmid vectors or by mechanisms such as homologous recombination, leading to multidrug resistance [4]. Over the past 20 years, ESBL-EC has widely spread worldwide and is no longer restricted to infections in hospital wards, and the prevalence of COUTIs caused by ESBL-EC is continuously increasing [1, 2].

Epidemiological studies have shown marked differences in the transmission of ESBL-EC, mainly because ESBL-EC has a high genetic diversity and diverse resistant strains may dominate in different regions and populations [1]. To understand the spread and differences of COUTIs caused by ESBL-EC in various regions in the last two decades, we referred to a large and reliable literature. Two studies in China reported the prevalence of ESBL-EC in COUTIs [6, 7]. In 2021, a prospective multicenter study in East China [6] reported the prevalence of ESBL-EC in communities in detail, comprising 1760 UTI cases from 19 hospitals; the detection rate of ESBL *Enterobacteriaceae* was 37.2%. The detection rate of community-acquired ESBL-EC cases was 22% in a retrospective study from Tongren Hospital, Beijing, China [7]. A similar pattern has been reported in several European countries, with a study from the Glasgow region of Scotland, UK, published in 2011 indicating a detection rate of ESBL *Enterobacteriaceae* of 7.5% in urine samples [8]. The detection rate of ESBL-EC in COUTIs increased from 0.47% in 2000 to 1.7% in 2014 in Spain [9]. A 9-year retrospective Australian study revealed a 44% increase in the proportion of ESBL-EC in individuals with UTIs caused by *E. coli* from 4.6% in 2006 to 6.6% in 2014 [10]. The prevalence of ESBL-EC has also been reported in countries in West Asia, with a report from Turkey in 2019 revealing a 50.5% detection rate of ESBL-EC in UTIs [11]. In 2018, a two-center cross-sectional study from Amman in Jordan reported a detection rate as high as 62% [12]. A multicenter study from North America reported a 3.9% detection rate of ESBL-EC in patients with community-associated infections [13], and another study from California reported a 5.9% detection rate in patients with UTIs [14]. In the present study, we reviewed all cases of COUTIs caused by *E. coli* in the Chongqing region over the past 5 years and found that the detection rate of ESBL-EC was 48.7%, which was higher than that in East China and Beijing, much higher than that in the United Kingdom, Spain, Australia, and the United States; and lower than that in Turkey and Jordan.

The high detection rate of ESBL-EC in the community may be associated with the clinical characteristics of the local infected population and the previous healthcare and antibiotic usage patterns of patients. In the present study, the proportion of ESBL-positive female patients was 74%, which was much higher than that of male patients. This finding is consistent with those of two

reports from East China and Beijing, wherein the number of ESBL-positive female patients was more than 80% [6, 7]. Moreover, women are more susceptible to UTIs for reasons associated with the physiological anatomy and estrogen levels of women [16, 17]. In terms of anatomy, the female urethra is relatively shorter than that of males and closer to the anus, increasing the chance of bacterial migration from the intestine to the urinary tract. Postmenopausal women are more susceptible to ascending UTIs due to changes in the urinary and vaginal microbiota because of reduced estrogen levels, with blooms of enterobacterial flora [17]. Oral or topical estrogen preparations are used to prevent recurrent UTIs in postmenopausal women [17, 18]. In the present study, most women were infected with COUTIs caused by ESBL-EC, and the patients' age was mainly over 60 years old, which is consistent with the fact that menopausal women are more susceptible to UTIs.

In the present study, the mean age of the patients was  $(64 \pm 13)$  years, and 62.0% (119/192) of the patients were aged 60 years and older. The vast majority of patients had underlying comorbidities, including diabetes, hypertension, urinary stones, parenchymal tumors, and others. Regarding the risk factors, 19.3% of patients had a history of urologic surgery, 18.2% had an indwelling catheter outside hospital, 28.1% were hospitalized within 6 months, and 35.9% used antibiotics within 6 months.

Univariate analysis revealed that parenchymal tumor, history of urolithiasis stone fragmentation, history of urological surgery, hospitalization within 6 months, indwelling catheter outside hospital, and antibiotic use (mainly third-generation cephalosporins) within 6 months were factors significantly associated with COUTIs caused by ESBL-EC ( $P < 0.05$ ). Multivariate analysis revealed that a history of urolithiasis stone fragmentation, urological surgery, indwelling catheter outside hospital, hospitalization within 6 months, and use of third-generation cephalosporins were independent risk factors for COUTIs caused by ESBL-EC. Although these findings are similar to those of previous studies [6, 7, 10-13, 19], there are still some differences. Furthermore, age is one of the possible risk factors [10, 11], and ESBL-positive patients were older than ESBL-negative patients in our study; however, the age difference was not statistically significant in the regression analysis ( $P = 0.088$ ). Prostatic hyperplasia is one of the possible risk factors [6], and more patients with prostatic hyperplasia were ESBL-positive than ESBL-negative; however, the difference was not significant in the regression analysis ( $P = 0.065$ ). Clinically, patients with prostatic hyperplasia present with urinary tract obstruction and urine retention and need more frequent catheterization maneuvers, which undoubtedly increases the risk of ESBL-EC infection. Nonetheless, our findings did not include prostatic hyperplasia as one of the independent risk factors, possibly due to the low sample size of male patients and a smaller number of patients with prostatic hyperplasia. This led to some deviation in the statistical results.

The most difficult part of UTI treatment is the increase in bacterial resistance, and the multidrug resistance of ESBL-EC makes the choice of therapeutic agents narrower and limited, which, in turn, increases the difficulty of treatment. In the present study, we statistically evaluated the results of susceptibility testing in 192 ESBL-positive patients. The results showed that carbapenems, including imipenem, meropenem, and ertapenem, had very strong antimicrobial activity in vitro, with 100%

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

251 sensitivity. Aminoglycoside antimicrobials showed a wide variation in the antimicrobial activity; the  
252 sensitivity of amikacin was excellent, reaching 100%, and that of gentamicin and tobramycin was  
253 64.4% and 54.4%, respectively. Nitrofurantoin, a nitrofuran, had a sensitivity of 87.9%. The  
254 sensitivity of piperacillin/tazobactam was 95.3%.

255 The treatment guidelines on multidrug-resistant bacteria issued by the Infectious Diseases Society of  
256 America in 2022 indicated that carbapenems have strong antibacterial activity against ESBL-  
257 producing *Enterobacteriaceae* and can be the first choice of treatment for pyelonephritis and  
258 complicated UTI caused by ESBL-producing *Enterobacteriaceae* [5]. In addition,  
259 piperacillin/tazobactam, a commonly used empirical therapeutic agent, demonstrated good  
260 antibacterial activity against multiple ESBL-producing *Enterobacteriaceae* [20]. However,  
261 compared with the in vitro efficacy of carbapenems, piperacillin/tazobactam is slightly less effective  
262 [5], which is consistent with the results of our study. It is important to note that the prevalence of  
263 carbapenem-resistant *Enterobacteriaceae* is also constantly increasing [21] and that repeated  
264 carbapenem use is a major contributing factor to the increasing prevalence of carbapenem-resistant  
265 *Enterobacteriaceae* [22]. Therefore, we preferentially use piperacillin/tazobactam for some patients  
266 with COUTIs caused by ESBL-ECs who are less symptomatic, thus reducing the frequency of  
267 carbapenem use.

268 Currently, the commonly used cephalosporins for the treatment of infections are not very effective in  
269 treating infections caused by ESBL-EC. In the present study, only the second-generation  
270 cephalosporin cefotetan had a high sensitivity (96.6%); third-generation cephalosporins have  
271 developed obvious resistance, and the resistance for ceftriaxone and cefixime reached 100%.

272 Combined with the risk factor analysis in this study, the use of third-generation cephalosporins is an  
273 independent risk factor for COUTIs caused by ESBL-EC, and we assume that there may be a  
274 situation of transitional third-generation cephalosporin use in this region and that the widespread use  
275 of third-generation cephalosporins will induce the emergence of new ESBL strains. Thus, the use of  
276 third-generation cephalosporins should be reduced in response to community-acquired infections,  
277 particularly COUTIs caused by ESBL-EC, to avoid inducing more ESBL-producing.

278 The study has some limitations. Firstly, our investigation focused on patients with COUTIs,  
279 excluding those with hospital-acquired urinary tract infections. Therefore, we could not compare the  
280 difference of epidemiological data between COUTIs and hospital acquired UTIs. Secondly, we only  
281 compiled statistics and analyzed the drug resistance in the ESBL-positive group without comparing  
282 the differences in drug resistance between the ESBL-positive and ESBL-negative groups. Thirdly, we  
283 employed the double-disk synergy test to confirm the phenotype of ESBL-producing *Escherichia coli*  
284 strains without conducting gene sequencing at the molecular level. Consequently, the resistance genes  
285 and virulence genes of ESBL-producing *Escherichia coli*, as well as the correlation between them,  
286 were not identified. Fourthly, this study is retrospective and relies on existing data, which may be  
287 subject to issues such as data quality, selection bias, and confounding factors. Additionally, due to  
288 limitations in sample size, we did not perform a prior sample size calculation. Instead, we simply  
289 included all eligible samples from the past five years, which may have reduced the statistical power  
290 of our findings.



291

## 292 5 Conclusions

293 The positive detection rate of COUTIs caused by ESBL-EC in this study was high; history of  
294 urolithiasis stone fragmentation, urological surgery, indwelling catheter outside hospital,  
295 hospitalization within 6 months, and use of third-generation cephalosporins were independent risk  
296 factors for COUTIs caused by ESBL-EC. The susceptibility profile suggested significant resistance  
297 to penicillins, cephalosporins, and quinolones; however, carbapenems and amikacin showed 100%  
298 sensitivity.

### 299 Ethical Approval

300 This study was approved by the Ethics Commission of The People's Hospital of Dazu District (No.  
301 2023LLSC0309).

### 302 Authors' contributions

303 YLZ and BLL conceived the study. HLL and YLZ collected the data. LHL and JW analyzed the  
304 data. BLL and YLZ wrote this article. JW and HX revised it. HX supervised study conduct. All the  
305 authors have read and approved the final version of this manuscript. JW are responsible for the  
306 overall content (as guarantor).

### 307 Funding

308 The study was supported by The First batch of key Disciplines On Public Health in Chongqing  
309 (YWBF2022072).

### 310 Declaration of Competing Interest

311 The authors declare that there are no competing interests.

### 312 Acknowledgments

313 We acknowledge to all members of the public and patients who have shown interest in and  
314 participated in this research. We acknowledge all health-care workers involved in the diagnosis and  
315 treatment of patients in Dazu Chongqing. We thank the clinical laboratory department from The  
316 People's Hospital of Dazu District, and We thank Medjaden Inc. for its assistance in the preparation  
317 of this manuscript.

### 318 Patient and Public Involvement

319 Patients and their guardians were not involved in the design and implementation of our study.  
320 Patients were not invited to contribute to the writing or editing of this manuscript. We recruited  
321 patients who were willing to participate in this study through various methods, including email,

telephone interviews, and face-to-face communication. We plan to write popular science articles based on the findings of this study and disseminate them to patients and the public through official channels of hospitals and regional CDCs, as well as by conducting educational lectures in infectious disease departments.

**Availability of Data and Materials**

The data is available upon reasonable request from the corresponding author Jing Wu (2861914532@qq.com).

**References**

[1] Karlowsky JA, Lob SH, DeRyke CA, et al. Prevalence of ESBL non-CRE Escherichia coli and Klebsiella pneumoniae among clinical isolates collected by the SMART global surveillance programme from 2015 to 2019. *Int J Antimicrob Agents*. 2022;59(3):106535. doi:10.1016/j.ijantimicag.2022.106535

[2] Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. *Lancet Infect Dis*. 2008;8(3):159-166. doi:10.1016/S1473-3099(08)70041-0

[3] Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. *Clin Microbiol Rev*. 2001;14(4):933-951. doi:10.1128/CMR.14.4.933-951.2001

[4] Shah AA, Hasan F, Ahmed S, Hameed A. Extended-spectrum beta-lactamases (ESbLs): characterization, epidemiology and detection. *Crit Rev Microbiol*. 2004;30(1):25-32. doi:10.1080/10408410490266429

[5] Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum  $\beta$ -lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). *Clin Infect Dis*. 2022;75(2):187-212. doi:10.1093/cid/ciac268

[6] J. Quan, H. Dai, W. Liao et al., Etiology and prevalence of ESBLs in adult community-onset urinary tract infections in East China: A prospective multicenter study, *Journal of Infection*, <https://doi.org/10.1016/j.jinf.2021.06.004>

[7] Ludong Q, Shan C, Lihui M. Risk factors of urinary tract infection caused by extended-spectrum  $\beta$ -lactamase-producing escherichia coli[J]. *Chinese Journal of Nosocomiology*, 2011, 21(02):247-249.

[8] Khanna N, Boyes J, Lansdell PM, Hamouda A, Amyes SG. Molecular epidemiology and antimicrobial resistance pattern of extended-spectrum- $\beta$ -lactamase-producing Enterobacteriaceae in Glasgow, Scotland. *J Antimicrob Chemother*. 2012;67(3):573-577. doi:10.1093/jac/dkr523

[9] Calbo E, Román V, Xercavins M, et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. *J Antimicrob Chemother*. 2006;57(4):780-783. doi:10.1093/jac/dkl035

[10] Toner L, Papa N, Aliyu SH, Dev H, Lawrentschuk N, Al-Hayek S. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospital urinary tract infections: incidence and antibiotic susceptibility profile over 9 years. *World J Urol*. 2016;34(7):1031-1037. doi:10.1007/s00345-015-

- 1718-x
- [11] Tüzün T, Sayın Kutlu S, Kutlu M, Kaleli İ. Risk factors for community-onset urinary tract infections caused by extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli*. *Turk J Med Sci*. 2019;49(4):1206-1211. Published 2019 Aug 8. doi:10.3906/sag-1902-24
- [12] Al-Jamei SA, Albsoul AY, Bakri FG, Al-Bakri AG. Extended-spectrum  $\beta$ -lactamase producing *E. coli* in urinary tract infections: A two-center, cross-sectional study of prevalence, genotypes and risk factors in Amman, Jordan. *J Infect Public Health*. 2019;12(1):21-25. doi:10.1016/j.jiph.2018.07.011
- [13] Doi Y, Park YS, Rivera JJ, et al. Community-associated extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli* infection in the United States. *Clin Infect Dis* 2013;56:641–8.
- [14] Frazee BW, Trivedi T, Montgomery M, Petrovic DF, Yamaji R, Riley L. Emergency Department Urinary Tract Infections Caused by Extended-Spectrum  $\beta$ -Lactamase-Producing Enterobacteriaceae: Many Patients Have No Identifiable Risk Factor and Discordant Empiric Therapy Is Common. *Ann Emerg Med*. 2018;72(4):449-456. doi:10.1016/j.annemergmed.2018.05.006
- [15] CLSI Performance standards for antimicrobial susceptibility testing. CLSI Supplement M100. 28th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2018.
- [16] Geerlings SE. Clinical Presentations and Epidemiology of Urinary Tract Infections. *Microbiol Spectr*. 2016;4(5):10.1128/microbiolspec.UTI-0002-2012. doi:10.1128/microbiolspec.UTI-0002-2012
- [17] Stamm WE. Estrogens and urinary-tract infection. *J Infect Dis*. 2007;195(5):623-624. doi:10.1086/511526
- [18] Perrotta C, Aznar M, Mejia R, Albert X, Ng CW. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. *Cochrane Database Syst Rev*. 2008;(2):CD005131. Published 2008 Apr 16. doi:10.1002/14651858.CD005131.pub2
- [19] Søgaard M, Heide-Jørgensen U, Vandenbroucke JP, Schönheyder HC, Vandenbroucke-Grauls CMJE. Risk factors for extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli* urinary tract infection in the community in Denmark: a case-control study. *Clin Microbiol Infect*. 2017;23(12):952-960. doi:10.1016/j.cmi.2017.03.026
- [20] Bush K, Macalintal C, Rasmussen BA, Lee VJ, Yang Y. Kinetic interactions of tazobactam with  $\beta$ -lactamases from all major structural classes. *Antimicrob Agents Chemother*. 1993;37(4):851-858. doi:10.1128/AAC.37.4.851
- [21] Zhang R, Liu L, Zhou H, et al. Nationwide Surveillance of Clinical Carbapenem-resistant Enterobacteriaceae (CRE) Strains in China. *EBioMedicine*. 2017;19:98-106. doi:10.1016/j.ebiom.2017.04.032
- [22] Sun Q, Yang X, Huang Y, et al. Risk factors and clinical impact associated with infections caused by different types of carbapenem-resistant *Klebsiella pneumoniae* in China: A clinical study from 2014 to 2017. *J Infect*. 2022;85(4):436-480. doi:10.1016/j.jinf.2022.05.045